Ravindra Majeti

Ravindra Majeti

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Ravindra Majeti

Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in Cell
Verified
Journal Article
Closed access
RMRavindra Majeti
Ravindra Majeti
MCMark P. Chao
Mark P. Chao
AAAsh A Alizadeh
Ash A Alizadeh
WPWendy W. Pang
Wendy W. Pang
SJSiddhartha Jaiswal
Siddhartha Jaiswal
IWIrving L. Weissman
Irving L. Weissman

15 August 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MCM Ryan Corces
M Ryan Corces
JBJason D Buenrostro
Jason D Buenrostro
BWBeijing Wu
Beijing Wu
PGPeyton G Greenside
Peyton G Greenside
SCSteven M Chan
Steven M Chan
HCHoward Y Chang
Howard Y Chang
Howard Chang, Ravindra Majeti and colleagues define the chromatin accessibility and transcriptional landscapes in 13 human primary blood cell types and in acute myeloid leukemia cells. They identify potential regulators governing hematopoietic differentiation and genetic elements linked to regulatory evolution in cancer cells. We define the chromatin accessibility and transcriptional landscapes in 13 human primary blood cell types that span the hematopoietic hierarchy. Exploiting the finding that the enhancer landscape better reflects cell identity than mRNA levels, we enable 'enhancer cytometry' for enumeration of pure cell types from complex populations. We identify regulators governing hematopoietic differentiation and further show the lineage ontogeny of genetic elements linked to diverse human diseases. In acute myeloid leukemia (AML), chromatin accessibility uncovers unique regulatory evolution in cancer cells with a progressively increasing mutation burden. Single AML cells exhibit distinctive mixed regulome profiles corresponding to disparate developmental stages. A method to account for this regulatory heterogeneity identified cancer-specific deviations and implicated HOX factors as key regulators of preleukemic hematopoietic stem cell characteristics. Thus, regulome dynamics can provide diverse insights into hematopoietic development and disease.

29 August 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MJMax Jan
Max Jan
TSThomas M. Snyder
Thomas M. Snyder
MCM. Ryan Corces-Zimmerman
M. Ryan Corces-Zimmerman
PVParesh Vyas
Paresh Vyas
IWIrving L. Weissman
Irving L. Weissman
RMRavindra Majeti
Ravindra Majeti
Given that most bone marrow cells are short-lived, the accumulation of multiple leukemogenic mutations in a single clonal lineage has been difficult to explain. We propose that serial acquisition of mutations occurs in self-renewing hematopoietic stem cells (HSCs). We investigated this model through genomic analysis of HSCs from six patients with de novo acute myeloid leukemia (AML). Using exome sequencing, we identified mutations present in individual AML patients harboring the FLT3-ITD (internal tandem duplication) mutation. We then screened the residual HSCs and detected some of these mutations including mutations in the NPM1, TET2, and SMC1A genes. Finally, through single-cell analysis, we determined that a clonal progression of multiple mutations occurred in the HSCs of some AML patients. These preleukemic HSCs suggest the clonal evolution of AML genomes from founder mutations, revealing a potential mechanism contributing to relapse. Such preleukemic HSCs may constitute a cellular reservoir that should be targeted therapeutically for more durable remissions.

3 February 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MCM. Ryan Corces-Zimmerman
M. Ryan Corces-Zimmerman
WHWan-Jen Hong
Wan-Jen Hong
IWIrving L. Weissman
Irving L. Weissman
BMBruno C. Medeiros
Bruno C. Medeiros
RMRavindra Majeti
Ravindra Majeti
Significance: A growing body of evidence has determined that somatic mutations in acute myeloid leukemia (AML) accumulate in self-renewing hematopoietic stem cells (HSCs). Thus, at the time of diagnosis, AML patients harbor preleukemic HSCs containing some, but not all, of the mutations in the downstream leukemia. Despite these findings, common patterns of preleukemic clonal evolution have not been determined, nor has the response of preleukemic HSCs to standard therapy been identified. This report addresses both of these questions determining that there are common patterns of preleukemic clonal evolution in AML, and that these preleukemic HSCs often survive standard induction chemotherapy. This study is of interest to the AML field, and broadly in cancer genomics as the principle that stem cells acquire initial cancer-initiating mutations is likely to extend beyond AML.

1 April 2012 in Current Opinion in Immunology
Verified
Journal Article
Closed access
MCMark P Chao
Mark P Chao
IWIrving L Weissman
Irving L Weissman
RMRavindra Majeti
Ravindra Majeti

1 December 2007 in Cell Stem Cell
Verified
Journal Article
Closed access
RMRavindra Majeti
Ravindra Majeti
CPChristopher Y. Park
Christopher Y. Park
IWIrving L. Weissman
Irving L. Weissman